The results were consistent across pre-defined subgroups stratified by type of DPP-4 inhibitor, type of cancer (including pancreatic and thyroid cancer), drug for comparison, trial duration, or baseline characteristics [64]. The gene discussed is DPP4; the disease is cancer.